These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32794656)

  • 1. Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes.
    Kuo CW; Hwu WL; Chien YH; Hsu C; Hung MZ; Lin IL; Lai F; Lee NC
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1455. PubMed ID: 32794656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
    Jang MA; Lee SH; Kim N; Ki CS
    Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of Carrier Frequency of Actionable Pathogenic Variants in Autosomal Recessive Genetic Diseases in the Turkish Cypriot Population.
    Gunsel AS; Ergoren MC; Kemal H; Kafshboran HR; Cerit L; Turgay A; Duygu H
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype.
    Kluska A; Kulecka M; Litwin T; Dziezyc K; Balabas A; Piatkowska M; Paziewska A; Dabrowska M; Mikula M; Kaminska D; Wiernicka A; Socha P; Czlonkowska A; Ostrowski J
    Liver Int; 2019 Jan; 39(1):177-186. PubMed ID: 30230192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actionable, pathogenic incidental findings in 1,000 participants' exomes.
    Dorschner MO; Amendola LM; Turner EH; Robertson PD; Shirts BH; Gallego CJ; Bennett RL; Jones KL; Tokita MJ; Bennett JT; Kim JH; Rosenthal EA; Kim DS; ; Tabor HK; Bamshad MJ; Motulsky AG; Scott CR; Pritchard CC; Walsh T; Burke W; Raskind WH; Byers P; Hisama FM; Nickerson DA; Jarvik GP
    Am J Hum Genet; 2013 Oct; 93(4):631-40. PubMed ID: 24055113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-frequency actionable pathogenic exome variants in an average-risk cohort.
    Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
    Chetruengchai W; Shotelersuk V
    J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of functional studies on exome sequence variant interpretation in early-onset cardiac conduction system diseases.
    Hayashi K; Teramoto R; Nomura A; Asano Y; Beerens M; Kurata Y; Kobayashi I; Fujino N; Furusho H; Sakata K; Onoue K; Chiang DY; Kiviniemi TO; Buys E; Sips P; Burch ML; Zhao Y; Kelly AE; Namura M; Kita Y; Tsuchiya T; Kaku B; Oe K; Takeda Y; Konno T; Inoue M; Fujita T; Kato T; Funada A; Tada H; Hodatsu A; Nakanishi C; Sakamoto Y; Tsuda T; Nagata Y; Tanaka Y; Okada H; Usuda K; Cui S; Saito Y; MacRae CA; Takashima S; Yamagishi M; Kawashiri MA; Takamura M
    Cardiovasc Res; 2020 Nov; 116(13):2116-2130. PubMed ID: 31977013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-Exome Sequencing Uncovers Novel Causative Variants and Additional Findings in Three Patients Affected by Glycogen Storage Disease Type VI and Fanconi-Bickel Syndrome.
    Eghbali M; Fatemi KS; Salehpour S; Abiri M; Saei H; Talebi S; Olyaei NA; Yassaee VR; Modarressi MH
    Front Genet; 2020; 11():601566. PubMed ID: 33505429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic gene variation spectrum and carrier screening for Wilson's disease in Qingdao area.
    Qiao L; Ge J; Li C; Liu Y; Hu C; Hu S; Li W; Li T
    Mol Genet Genomic Med; 2021 Aug; 9(8):e1741. PubMed ID: 34240825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WilsonGen a comprehensive clinically annotated genomic variant resource for Wilson's Disease.
    Kumar M; Gaharwar U; Paul S; Poojary M; Pandhare K; Scaria V; Bk B
    Sci Rep; 2020 Jun; 10(1):9037. PubMed ID: 32493955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review.
    Elfatih A; Mohammed I; Abdelrahman D; Mifsud B
    Physiol Genomics; 2021 Sep; 53(9):373-384. PubMed ID: 34250816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rate of secondary genomic findings in the Saudi population.
    Aloraini T; Alsubaie L; Alasker S; Al Muitiri A; Alswaid A; Eyiad W; Al Mutairi F; Ababneh F; Alfadhel M; Alfares A
    Am J Med Genet A; 2022 Jan; 188(1):83-88. PubMed ID: 34515413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais.
    Chetruengchai W; Phowthongkum P; Shotelersuk V
    BMC Med Genomics; 2024 Jan; 17(1):9. PubMed ID: 38167091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of recurrent pathogenic alleles using exome sequencing data: Proof-of-concept study of Russian subjects.
    Orlov IE; Laidus TA; Tumakova AV; Yanus GA; Iyevleva AG; Sokolenko AP; Bizin IV; Imyanitov EN; Suspitsin EN
    Eur J Med Genet; 2022 Feb; 65(2):104426. PubMed ID: 35026467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of pathogenic variants in clinically actionable genes in a founder population.
    Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
    Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1 in 38 individuals at risk of a dominant medically actionable disease.
    Haer-Wigman L; van der Schoot V; Feenstra I; Vulto-van Silfhout AT; Gilissen C; Brunner HG; Vissers LELM; Yntema HG
    Eur J Hum Genet; 2019 Feb; 27(2):325-330. PubMed ID: 30291343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental and clinically actionable genetic variants in 1005 whole exomes and genomes from Qatar.
    Jain A; Gandhi S; Koshy R; Scaria V
    Mol Genet Genomics; 2018 Aug; 293(4):919-929. PubMed ID: 29557500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.